Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection

Jong Won Choi, Junyong Park, SangHoon Ahn, Ki Tae Yoon, Heung Kyu Ko, Do Yun Lee, Jong Tae Lee, Kyung Sik Kim, Jin Sub Choi, KwangHyub Han, Chae Yoon Chon, doyoung kim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.

Original languageEnglish
Pages (from-to)564-569
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume32
Issue number6
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Hepatocellular Carcinoma
Safety
Disease-Free Survival
Recurrence
Neoplasms
Survival
Sepsis
Regression Analysis
Neoplasm Metastasis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Choi, Jong Won ; Park, Junyong ; Ahn, SangHoon ; Yoon, Ki Tae ; Ko, Heung Kyu ; Lee, Do Yun ; Lee, Jong Tae ; Kim, Kyung Sik ; Choi, Jin Sub ; Han, KwangHyub ; Chon, Chae Yoon ; kim, doyoung. / Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2009 ; Vol. 32, No. 6. pp. 564-569.
@article{2f3ff0e22149440ea9874d18d67b90e8,
title = "Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection",
abstract = "Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2{\%}) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5{\%}) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0{\%}, 16.7{\%}, and 13.4{\%} at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8{\%}, 53.6{\%}, and 31.6{\%} at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.",
author = "Choi, {Jong Won} and Junyong Park and SangHoon Ahn and Yoon, {Ki Tae} and Ko, {Heung Kyu} and Lee, {Do Yun} and Lee, {Jong Tae} and Kim, {Kyung Sik} and Choi, {Jin Sub} and KwangHyub Han and Chon, {Chae Yoon} and doyoung kim",
year = "2009",
month = "12",
day = "1",
doi = "10.1097/COC.0b013e3181967da0",
language = "English",
volume = "32",
pages = "564--569",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. / Choi, Jong Won; Park, Junyong; Ahn, SangHoon; Yoon, Ki Tae; Ko, Heung Kyu; Lee, Do Yun; Lee, Jong Tae; Kim, Kyung Sik; Choi, Jin Sub; Han, KwangHyub; Chon, Chae Yoon; kim, doyoung.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 32, No. 6, 01.12.2009, p. 564-569.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection

AU - Choi, Jong Won

AU - Park, Junyong

AU - Ahn, SangHoon

AU - Yoon, Ki Tae

AU - Ko, Heung Kyu

AU - Lee, Do Yun

AU - Lee, Jong Tae

AU - Kim, Kyung Sik

AU - Choi, Jin Sub

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - kim, doyoung

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.

AB - Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.

UR - http://www.scopus.com/inward/record.url?scp=73349099035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349099035&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181967da0

DO - 10.1097/COC.0b013e3181967da0

M3 - Article

C2 - 19564783

AN - SCOPUS:73349099035

VL - 32

SP - 564

EP - 569

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -